Target intelligence / Profile preview

NLR family pyrin domain-containing protein 3 inflammasome (NLRP3 inflammasome)

Target
NLRP3 inflammasome
Molecular classification
Multiprotein complex, Pattern recognition receptor (PRR) pathway component, Innate immune sensor complex, Other
01

Overview

The NLRP family pyrin domain-containing protein 3 inflammasome (NLRP3 inflammasome) is a cytosolic multiprotein complex that plays a central role in the innate immune system. It acts as a sensor for diverse pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), including microbial components, crystalline substances like uric acid or cholesterol crystals, environmental irritants such as asbestos or silica, extracellular ATP, mitochondrial dysfunction signals, and more. Upon activation through a two-step process involving priming via NF-kB signaling followed by assembly triggered by cellular stressors or damage signals, the NLRP3 inflammasome recruits adaptor ASC and pro-caspase‑1. This leads to caspase‑1 activation which cleaves pro-inflammatory cytokines pro‑IL‑1β and pro‑IL‑18 into their active forms. The resulting inflammatory cascade is essential for host defense but can also drive pathological inflammation implicated in diseases such as gout, type 2 diabetes complications, neurodegeneration, cardiovascular disorders like atherosclerosis, autoimmune conditions—and is thus considered an important therapeutic target for anti-inflammatory drug development.

Other names
NLRP3 complexCryopyrin inflammasomeNACHT, LRR and PYD domains-containing protein 3 inflammasomeNALP3 inflammasome
02

Mechanism of action

– Direct inhibition of NLRP3 oligomerization/activation – Blockade of ATPase activity in the NACHT domain – Disruption of ASC recruitment or speck formation – Suppression of upstream priming signals via NF-kB pathway inhibition

03

Biological functions

Immune responseInflammatory signalingCytokine maturation (IL-1β and IL-18)Cell death (pyroptosis)Signal transduction
04

Disease associations

InflammationInfectious diseaseNeurodegenerative diseaseCardiovascular disease (e.g., atherosclerosis)Gout and crystal-induced diseasesAutoimmune disorders
05

Safety considerations

Risk of immunosuppression/increased infection susceptibility due to broad suppression of innate immunity responsesPotential for off-target effects given the central role in inflammation across multiple tissues/diseases
06

Interacting drugs

MCC950 (CRID3)

6 more in the full profile.

07

Biomarkers

IL‑1β levels in serum/plasma/tissueIL‑18 levels in serum/plasma/tissueCaspase‑1 activation status

Beyond the preview

Go deeper on NLR family pyrin domain-containing protein 3 inflammasome (NLRP3 inflammasome).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLR family pyrin domain-containing protein 3 inflammasome (NLRP3 inflammasome).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call